{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["44(2)"],"submitter":["Xiyu LI"],"pubmed_abstract":["<h4>Objective</h4>To investigate the effectiveness and safety of Jiawei Xiaoyao pill (，JXP) in the treatment of symptoms associated with premenstrual syndrome (PMS).<h4>Methods</h4>A total of 144 regularly menstruating women with PMS were recruited at 8 sites in China from August 2017 to December 2018, and randomized to receive either a JXP or a matching placebo (12 g/d, 6 g twice a day) for 3 menstrual cycles. The primary indicator was the reduced Daily Record of Severity of Problems (DRSP) scores in the luteal phase after 3 months of treatment. The safety outcomes included clinical adverse events (AEs), adverse reactions (ARs), changes in vital signs, and laboratory tests.<h4>Results</h4>JXP surpassed the placebo in reducing DRSP scores (psychological/somatic dysfunction) in the luteal p"],"journal":["Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan"],"pagination":["373-380"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10927397"],"repository":["biostudies-literature"],"pubmed_title":["Effectiveness and safety of Jiawei Xiaoyao pill in the treatment of premenstrual syndrome (liver depression, spleen deficiency, and blood-heat syndrome): a multi-center, randomized, placebo-controlled trial."],"pmcid":["PMC10927397"],"pubmed_authors":["Xiyu LI","Junping YU","Jian S","Quanfang N","Yun S","Ting Z","Guifen LI","Zhuangjin Z","Yi XU","Lifen L","Yanhong Y"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness and safety of Jiawei Xiaoyao pill in the treatment of premenstrual syndrome (liver depression, spleen deficiency, and blood-heat syndrome): a multi-center, randomized, placebo-controlled trial.","description":"<h4>Objective</h4>To investigate the effectiveness and safety of Jiawei Xiaoyao pill (，JXP) in the treatment of symptoms associated with premenstrual syndrome (PMS).<h4>Methods</h4>A total of 144 regularly menstruating women with PMS were recruited at 8 sites in China from August 2017 to December 2018, and randomized to receive either a JXP or a matching placebo (12 g/d, 6 g twice a day) for 3 menstrual cycles. The primary indicator was the reduced Daily Record of Severity of Problems (DRSP) scores in the luteal phase after 3 months of treatment. The safety outcomes included clinical adverse events (AEs), adverse reactions (ARs), changes in vital signs, and laboratory tests.<h4>Results</h4>JXP surpassed the placebo in reducing DRSP scores (psychological/somatic dysfunction) in the luteal p","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-03-18T14:14:21.892Z","creation":"2025-08-24T03:05:15.581Z"},"accession":"S-EPMC10927397","cross_references":{"pubmed":["38504543"],"doi":["10.19852/j.cnki.jtcm.20231110.003"]}}